These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34831101)

  • 1. Molecular Mechanisms of Multi-Organ Failure in COVID-19 and Potential of Stem Cell Therapy.
    Bhalerao A; Raut S; Noorani B; Mancuso S; Cucullo L
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of Mesenchymal Stem Cells for the Treatment of Cytokine Storm due to COVID-19.
    Li X; Yan M; Chen J; Luo Y
    Biomed Res Int; 2021; 2021():3178796. PubMed ID: 34840969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
    Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
    Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
    Cheon SY; Koo BN
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm.
    Shadvar K; Tagizadiyeh A; Gamari AA; Soleimanpour H; Mahmoodpoor A
    Blood Purif; 2021; 50(3):405-407. PubMed ID: 33171470
    [No Abstract]   [Full Text] [Related]  

  • 7. Current Status and Future Prospects of Perinatal Stem Cells.
    Torre P; Flores AI
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
    Pourgholaminejad A; Pahlavanneshan S; Basiri M
    Scand J Immunol; 2022 Feb; 95(2):e13131. PubMed ID: 34936112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reinforcing the Team: A Call to Critical Care Nephrology in the COVID-19 Epidemic.
    Rizo-Topete LM; Husain-Syed F; Ronco C
    Blood Purif; 2021; 50(3):275-278. PubMed ID: 32957107
    [No Abstract]   [Full Text] [Related]  

  • 10. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
    Gu J; Zhao Q; Han Z; Han Z
    Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
    Barros I; Silva A; de Almeida LP; Miranda CO
    Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
    Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
    Loganathan S; Kuppusamy M; Wankhar W; Gurugubelli KR; Mahadevappa VH; Lepcha L; Choudhary AK
    Respir Physiol Neurobiol; 2021 Jan; 283():103548. PubMed ID: 32956843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19.
    Jeyaraman M; John A; Koshy S; Ranjan R; Anudeep TC; Jain R; Swati K; Jha NK; Sharma A; Kesari KK; Prakash A; Nand P; Jha SK; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Feb; 1867(2):166014. PubMed ID: 33232817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options.
    Nazerian Y; Ghasemi M; Yassaghi Y; Nazerian A; Hashemi SM
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109428. PubMed ID: 36379152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling Cytokine Storm Is Vital in COVID-19.
    Tang L; Yin Z; Hu Y; Mei H
    Front Immunol; 2020; 11():570993. PubMed ID: 33329533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells.
    Wang L; Li Y; Xu M; Deng Z; Zhao Y; Yang M; Liu Y; Yuan R; Sun Y; Zhang H; Wang H; Qian Z; Kang H
    Front Immunol; 2021; 12():726909. PubMed ID: 34394132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation using CONVEHY® for COVID-19: from the storm to the cytokine anticyclone.
    García-Hernández R; Espigares-López MI; Miralles-Aguiar F; Gámiz-Sánchez R; Arroyo Fernández FJ; Pernia Romero A; Torres LM; Calderón Seoane E;
    Rev Esp Anestesiol Reanim (Engl Ed); 2021 Feb; 68(2):107-112. PubMed ID: 33455739
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.
    Lee YY; Park HH; Park W; Kim H; Jang JG; Hong KS; Lee JY; Seo HS; Na DH; Kim TH; Choy YB; Ahn JH; Lee W; Park CG
    Biomaterials; 2021 Jan; 267():120389. PubMed ID: 33130319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.
    Fudim M; Qadri YJ; Ghadimi K; MacLeod DB; Molinger J; Piccini JP; Whittle J; Wischmeyer PE; Patel MR; Ulloa L
    J Cardiovasc Transl Res; 2020 Dec; 13(6):894-899. PubMed ID: 32458400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.